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INTRODUCTION
Larygopharyngeal reflux (LPR) is a retrograde flow of gastric 
contents into the laryngopharynx, which may result in posterior 
laryngitis with a constellation of laryngeal symptoms and signs 
(1). LPR is a commonly encountered problem in otolaryngologic 
practice. Therefore, it is of significant interest to otolaryngolo-
gists (2); LPR is diagnosed in approximately 10% of patients 
presenting to the outpatient clinic and more than 50% of pa-
tients with voice complaints (3).
  A diagnosis of LPR is usually based on the response of symp-
toms to empirical treatment with proton pump inhibitors (PPI). 
Further investigative modalities, including 24 hour pH monitor-
ing and multi-channel impedance studies are generally reserved 
for cases of treatment failure (4). However, signs and symptoms 
of LPR are not specific and can be produced by a wide variety 
of other conditions, including postnasal drip, infectious agents, 
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and chemical irritants; therefore, its diagnosis may be difficult (5). 
In addition, laryngeal findings are not always associated with 
symptom severity (6) and correlation between signs and symp-
toms of LPR is particularly poor when monitoring therapeutic 
outcomes (7). As a result, controversy remains regarding how to 
confirm diagnosis and what comprises appropriate medical 
management (8). 
  Belafsky et al. (9, 10) developed two validated assessment in-
struments in the hope of providing a more consistent and reli-
able diagnosis of LPR; a nine-item reflux symptom index (RSI) 
and an eight-item reflux finding score (RFS). Many recent arti-
cles have suggested the treatment algorithm or clinical pathway 
primarily based on these questionnaires; therefore, both indices 
are believed to be widely used (11). However, there are some 
controversies regarding their sensitivity, specificity, and correla-
tion between the two instruments, as well as inter-rater or intra-
rater reliability in assessment of laryngeal findings (12, 13). Ac-
cording to one of recent nation-wide survey, more than 90% of 
otolaryngologists do not use these indices during their daily 
practice (14). 
  Although H2-receptor antagonists, prokinetic agents, and mu-
cosal cytoprotectants are still used, PPIs are the mainstay of 
medical treatment (15). A 3-month empirical trial of PPI is gen-
erally regarded as a cost-effective approach to initial assessment 
and management of LPR (16). However, there are some contro-
versies regarding their efficacy as well as the length of the thera-
peutic trial (17). Although a few trials have analyzed predictors 
of response to PPI treatment, there are no established predictors 
of response to PPI therapy (18-21).
  The authors conducted a prospective, multi-center, open-label 
observational study to determine the short-term benefits of ra-
beprazol (22) medication on LPR. The authors also wanted to 
know if scores on the RSI and the RFS could be combined to 
identify subgroups of patients that are more likely to improve 
with this medication. 
MATERIALS AND METHODS
A prospective, multi-institutional, and open-label observational 
study was designed to investigate the effects of rabeprazole short-
term treatment in patients with LPR. Fifty-one Korean Otolar-
yngology Board certified specialists, who were working at 40 
different nation-wide secondary or tertiary referral hospitals, 
participated in this study. Prior to the start of the study, IRB per-
mission was obtained from each institution. A consensus meet-
ing was provided in order to obtain a higher inter- and intra-rat-
er reliability in scoring of RFS. In the meeting, detailed informa-
tion on the original description of RFS by Belafsky et al. (10) 
was reiterated to the participating investigators. They were asked 
to repeatedly rate 8 individual items of RFS while reviewing la-
ryngoscopic pictures or video clips of 7 different representative 
cases of LPR. An electronic balloting system enabled them to 
obtain instantaneous feedback by checking the statistics of other 
investigators’ rating scores.
  When patients were clinically diagnosed as having LPR, and 
therfore, PPI medication was determined to be necessary for it, 
the study protocol was explained to those patients and patients’ 
consents were obtained. Rabeprazol was given to patients with-
out changing each investigator’s usual patterns of practice; a to-
tal dosage (10 or 20 mg q.d.) per day, administration intervals, 
and concomitant use of other drugs. Patients were asked to re-
visit the clinic at 4, 8, and 12 weeks after the first visit. RSI and 
RFS were obtained at each visit. Collected information regard-
ing the patients’ demographic profiles, drug administration, re-
sponse, and side effects was submitted to a central database 
server through a web-based electronic-case report form.
  Patients who met any of following criteria were excluded 
from the study; a history of taking PPI within one month, hy-
persensitivity to any Pariet (Janssen Korea, Hwaseong, Korea) 
ingredient (rabeprazole sodium) or benzimidazole, moderate to 
severe hepatic functional impairment, and pregnant or lactating 
women. From September 2007 to January 2008, a total of 1,142 
patients were initially enrolled in the study, and 455 (40%) pa-
tients completed the required follow-up visits; they revisited the 
clinics with an interval of 4 weeks and until more than the 12th 
week following the initial enrollment in this study.
  To see the effects of rabeprazole along the treatment period, 1) 
values of individual RSI and RFS item or total RSI and RFS 
scores were compared with those obtained at the previous visit 
using a mixed model for repeated measurements. 2) Trends of 
RSI and RFS changes along the treatment period were analyzed 
using a generalized estimation equation. 3) To minimize inter-rat-
er variability of rating scores, relative RSI and RFS were com-
pared. When post-treatment total RSI or total RFS showed a de-
crease of 50% or more than initial pre-treatment RSI or RFS, 
those patients were categorized as responders. A trend of im-
provement was evaluated by using the number of responders at 
4, 8, and 12 weeks. 
  According to the initial scores of total RSI and RFS, patients 
were divided into 4 subgroups; RSI
highRFS
high, RSI
lowRFS
high, RSI-
highRFS
low, and RSI
lowRFS
low. RSI
high was defined as when total 
RSI is equal to or greater than 14 and RFS
high was defined as 
when total RFS is equal or greater than 8 (8). The cut-off values 
of 8 for RFS and 14 for RSI were adopted for the subgrouping 
of patients according to a recommendation of the previous 
guideline (8). Repeated measures of ANOVA (SPSS ver. 14.0; 
SPSS Inc., Chicago, IL, USA) was used to determine which sub-
group will obtain more benefit with rabeprazole medication. 
RESULTS
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were initially enrolled. Their mean age was 51.9 years old. At 4, 
8, and 12 weeks after enrollment, 78% (n=881), 57% (n=661), 
and 40% (n=455) of the 1,142 enrolled patients revisited out-
patient clinics and completed the required evaluations. At 12 
weeks, 45%, 39%, 29%, and 39% of RSI
highRFS
high, RSI
lowRF-
S
high, RSI
highRFS
low, and RSI
lowRFS
low subgroup populations were 
followed up, respectively. 
  Pre-treatment RSI score was 15.13±8.19 (mean±SD), which 
significantly decreased to 10.77±7.19, 8.00±6.67, and 5.83±
6.03 after 4, 8, and 12 weeks of rabeprazole treatment, respec-
tively (Table 1). After 12 weeks of rabeprazole medication, 9 in-
dividual items of RSI as well as total RSI showed significant im-
provement (P<0.0001). There was also a trend toward significant 
improvement in RSI along the time period (P<0.0001) (Fig. 1). 
  As like the RSI, 8 individual items of RFS as well as total RFS 
showed significant improvement (P<0.0001) after 12 weeks of 
rabeprazole medication, when compared with RFS of pre-treat-
ment (Table 2). There was also a trend toward significant im-
provement in RFS along the time period (P<0.0001) (Fig. 2). 
  Responders (greater than 50% improvement in RSI or RFS) 
increased along with the treatment period, and a trend toward 
improvement was statistically significant (P<0.0001). Respond-
ers of RSI and RFS after 12 weeks of treatment reached 75% 
and 57% in numbers, respectively (Table 3). 
  All of the 4 subgroups showed a tendency toward improve-
ment in RSI and RFS along the period of rabeprazole medica-
tion (Figs. 1, 2). Within each group, RSI showed significant im-
provement along the time period (P<0.0001). However, no dif-
Table 1. Changes of reflux symptom index (RSI) before and after 4, 8, and 12 weeks of rabeprazole medication
Pre-treatmnet 
(n=1,142)
4 wk (n=881) 8 wk (n=661) 12 wk (n=455)
P-value for before 
and after 12 wk
P-value for 
trend
Hoarseness or voice problem 2.19±1.62 1.54±1.41 1.20±1.30 0.91±1.15 <0.0001 <0.0001
Throat clearing 2.33±1.60 1.75±1.30 1.22±1.19 0.92±1.10 <0.0001 <0.0001
Excess throat mucus or postnasal drip 1.75±1.57 1.26±1.30 0.95±1.21 0.67±1.08 <0.0001 <0.0001
Difficult swallowing 0.69±1.16 0.51±0.94 0.39±0.86 0.27±0.66 <0.0001 <0.0001
Coughing after eating or lying down 1.04±1.38 0.67±0.99 0.52±0.90 0.35±0.80 <0.0001 <0.0001
Breathing difficulties or choking episodes 0.98±1.43 0.67±1.07 0.45±0.86 0.33±0.76 <0.0001 <0.0001
Troublesome or annoying cough 1.42±1.53 1.05±1.24 0.76±1.07 0.51±0.91 <0.0001 <0.0001
Sensations of something sticking or a lump in 
your throat
2.96±1.62 2.13±1.48 1.66±1.35 1.37±1.23 <0.0001 <0.0001
Heartburn, chest pain, indigestion, or stomach 
acid coming up
1.75±1.62 1.20±1.28 0.86±1.13 0.52±0.88 <0.0001 <0.0001
Total RSI 15.13±8.19 10.77±7.19 8.00±6.67 5.83±6.03 <0.0001 <0.0001
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Fig. 1. Changes of reflux symptom index (RSI) in each subgroup with 
short-term rabeprazole medication. According to initial scores of to-
tal RSI and reflux finding score (RFS), patients were divided into 4 
subgroups. Changes of score on RSI were plotted along the 12 
weeks period of rabeprazole medication in both a total patient co-
hort and each subgroup. All of the 4 subgroups as well as the total 
patient cohort showed a tendency toward improvement in RSI along 
the treatment period (P<0.0001). 
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Fig. 2. Changes of reflux finding scores (RFS) in each subgroup with 
short-term rabeprazole medication. According to initial scores of to-
tal reflux symptom index (RSI) and RFS, patients were divided into 4 
subgroups. Changes of score on RFS were plotted along the 12 
weeks period of rabeprazole medication in both a total patient co-
hort and each subgroup. All of the 4 subgroups as well as the total 
patient cohort showed a tendency toward improvement in RFS 
along the treatment period (P<0.0001).Shin M-H et al.: Short-term Effects of Rabeprazole in LPR    31
ference of RSI improvement was observed between the sub-
groups (P=0.235) (Table 4). As like with RSI, RFS showed sig-
nificant improvement along the time period (P<0.0001) within 
each group. In contrast to RSI, a difference of RFS improvement 
was observed between the subgroups (P=0.002). Further analy-
ses revealed that the responders in RFS were more in the RSI ≥ 
14 subgroup (54.00%), when compared with the RSI<14 sub-
group (43.04%) with a P-value of 0.012. However, no differ-
ence was observed between the RFS ≥ 8 (48.15%) and RFS<8 
(50.80%) subgroups (P=0.816) (Table 5). 
DISCUSSION
Treatment of LPR often suffers from poor patient compliance, 
and therfore, poor symptom improvement (23). In this study, 
approximately 40% (n=455) of initially enrolled patients were 
followed up across a period of 12 weeks with PPI treatment. 
Among those patients, significant RSI and RFS improvement 
(more than 50%) was observed in 75% and 57% of them, re-
spectively. We could not investigate the reasons why the other 
60% of the enrolled patients were lost from follow-up, which is 
one of the greatest weak points of this study. Even though fol-
low-up rates of each subgroup did not differ significantly from 
each other (range from 29% to 45%), selection bias might oc-
cur between each subgroup, and therefore, it might induce a bi-
ased conclusion regarding the response to PPI treatment. In ad-
dition, we did not check the patients’ compliance regarding 
medications or behavioral modification, which is another weak 
point of this study. Since behavioral modification itself may re-
sult in marked improvement or complete resolution of patients’ 
discomfort, the compounding effect of it should not be over-
looked. According to a study associated with the compliance of 
LPR patients, only about 50% of patients are taking their medi-
cations as prescribed and compliance varies more widely with 
regard to behavioral modifications (24). Therefore, simplification 
of the treatment regimen and shortening the period of medical 
management may increase patient compliance. In this respect, 
prediction of when and how many LPR patients will improve 
with PPI empirical treatment may be very important. 
  In this study, reflux symptoms improved before reflux finding 
did, which coincides with results of a previous report (6). Signifi-
cant RSI improvement was obtained in 29%, 58%, and 75% of 
patients after 4, 8, and 12 weeks of PPI medication. In contrast 
to RSI, at least 12 weeks of PPI medication was required in or-
der to obtain significant RFS improvement in 57% of patients. 
Therefore, to assess the effectiveness of PPI treatment in patients 
with LPR, 2 to 3 months of empirical medication will be needed 
before confirming favorable changes in reflux symptoms and 
findings with a probability of higher than 57% to 58%. Howev-
er, it is worth remembering that approximately 29% of patients 
Table 2. Changes of reflux finding scores (RFS) before and after 4, 8, and 12 weeks of rabeprazole medication
Pre-treatmnet 
(n=1,142)
4 wk (n=881) 8 wk (n=661) 12 wk (n=455)
P-value for before 
and after 12 wk
P-value for 
trend
Pseudosulcus (infraglottic edema) 0.88±0.99 0.79±0.98 0.63±0.93 0.55±0.89 <0.0001 <0.0001
Ventricular obliteration 1.22±1.29 1.06±1.15 0.85±1.05 0.60±0.92 <0.0001 <0.0001
Erythema/hyperemia 1.85±1.16 1.49±1.06 1.17±1.09 0.95±1.03 <0.0001 <0.0001
Vocal fold edema 1.34±0.93 1.00±0.78 0.76±0.71 0.55±0.66 <0.0001 <0.0001
Diffuse laryngeal edema 1.30±0.94 1.00±0.77 0.75±0.73 0.53±0.65 <0.0001 <0.0001
Posterior commissure hypertrophy 1.82±0.93 1.47±0.87 1.21±0.86 1.08±0.82 <0.0001 <0.0001
Granuloma/granulation 0.14±0.51 0.13±0.49 0.09±0.42 0.09±0.41 0.0003 <0.0001
Thick endolaryngeal mucus 0.59±0.91 0.36±0.77 0.23±0.64 0.15±0.53 <0.0001 <0.0001
Total RFS 9.13±4.39 7.30±3.73 5.68±3.55 4.50±3.14 <0.0001 <0.0001
Table 3. Numbers of responders after 4, 8, and 12 weeks of rabe-
prazole medication
4 wk 
(n=881)
8 wk 
(n=645)
12 wk 
(n=448)
P-value for 
trend
Responders of RSI 256 (29.06) 374 (57.98) 336 (75.00) <0.0001
Responders of RFS 142 (16.12) 271 (42.02) 256 (57.14) <0.0001
Values are presented as number (%).
RSI, reflux symptom index; RFS, reflux finding scores.
Table 5. Percentage of responders on reflux finding scores after 4, 8, 
and 12 weeks of rabeprazole medication
4 wk 
(n=881)
8 wk 
(n=661)
12 wk 
(n=455)
Within each 
group
Between 
groups
RSI≥14, RFS≥8 19.96 37.58 49.55 P<0.0001 P=0.0018
RSI<14, RFS≥8 24.68 42.45 56.35 P<0.0001
RSI≥14, RFS<8 12.55 31.35 30.61 P<0.0001
RSI<14, RFS<8 20.03 39.7 57.56 P<0.0001
RSI, reflux symptom index; RFS, reflux finding scores.
Table 4. Percentage of responders on reflux symptom index scores 
after 4, 8, and 12 weeks of rabeprazole medication
4 wk 
(n=881)
8 wk 
(n=661)
12 wk 
(n=455)
Within each 
group
Between 
groups
RSI≥14, RFS≥8 25.26 46.55 60.17 P<0.0001 P=0.2354
RSI<14, RFS≥8 22.14 37.35 56.02 P<0.0001
RSI≥14, RFS<8 39.53 58.57 64.42 P<0.0001
RSI<14, RFS<8 37.82 61.01 76.08 P<0.0001
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may obtain significant improvement in their reflux symptoms 
even with 4 weeks of PPI medication and that the number of 
symptom responders will increase along the treatment period of 
12 weeks. Moreover, even patients having low-RSI and/or low-
RFS may obtain benefit from PPI medications. Patients with 
contact ulcer or granuloma will be a good example of this; those 
patients usually have low-RSI (less than 14) and low-RFS (less 
than 8), however, many of them will improve with PPI medica-
tions.
  To the best of our knowledge, there are no established predic-
tors of response to PPI medication in patients with LPR. Base-
line anxiety levels and heartburn scores were relevant predictors 
of faster response to PPI (18). Presence of abnormalities in the 
inter-arytenoid mucosa and true vocal folds were associated with 
a favorable response to PPI therapy (19). However, the presence 
of reflux symptoms or reflux findings was not a reliable predic-
tor of good response to PPI (20, 21). In accordance with these 
previous reports, we could not define reliable symptoms or phys-
ical findings for prediction of response to PPI medication. In 
contrast, positive pharyngeal pH study may be associated with a 
better symptom response to PPI treatment (20, 21), even though 
24 hour pH monitoring and/or multi-channel impedance studies 
are generally reserved for cases of treatment failure (4). 
  In our study, all 4 subgroups showed significant improvement 
in their reflux symptoms and findings with PPI medication, 
which means that their pre-treatment RSI or RFS values are not 
useful predictors of the response to short-term PPI medication. 
This phenomenon may be explained in part by the placebo-ef-
fect, not only of the patients but also of the investigaters, since 
this study was conducted not as a blinded and not as a random-
ized design. A randomized, double-blinded, placebo-controlled 
study revealed improvement in RFS and RSI in both placebo 
and PPI groups after 6 weeks of treatment with PPI, even though 
improvements were greater in the PPI group in several parame-
ters (17). Subjective criteria for the diagnosis of LPR and no 
uniform criteria in the enrollment of patient could be another 
limitation of this study. No standardization in the dose of rabe-
prazole could be another variables. The effects of concomitant 
drug usage or co-morbidity were not taken into account while 
analyzing the response to PPI. Moreover, the effects of total 
dosage and dosing of PPI as well as the timing of PPI medica-
tion regarding to food intakes were also not adjusted before an-
alyzing the data, which could significantly influence on the out-
come of drug response, therefore, on the conclusion of this 
study. Unproven inter-rater and/or intra-rater reliability for as-
sessment of RFS might also be one of the reasons, even though 
the investigators were educated through a consensus meeting in 
order to reach a greater inter-rater reliability in scoring RFS. 
  Despite many constraints of this study, this is one of the few 
reports involving relatively large numbers of LPR patient (n=
1,142) as well as broad spectrum of physicians (n=40) as co-in-
vestigators with a prospective design, which probably can over-
ride the above mentioned weaknesses. In summary, the authors 
suggest that pre-treatment RSI and RFS are not reliable predic-
tors for the outcome of PPI treatment in the usual pattern of 
practice provided for LPR patients, which is largely based on the 
physical evaluation and history taking.
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